alirocumab vs rosuvastatin/ezetimibe
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of alirocumab and rosuvastatin/ezetimibe. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Praluent
Roszet
Praluent is a medicine that can lower cholesterol. It can also lower the risk of heart problems like heart attack or stroke in some adults.
Roszet contains rosuvastatin, which is a statin medicine. It helps lower bad cholesterol and reduce the risk of heart problems.
Praluent is used to lower LDL cholesterol (bad cholesterol). It is used along with diet and exercise in adults with high cholesterol. It is also used in adults and children 8 years and older who have a genetic condition that causes high cholesterol.
This medicine can help lower LDL cholesterol (bad cholesterol) if you have high cholesterol. It can also slow down the hardening of your arteries. Roszet can also lower triglycerides if you have high triglycerides.
Praluent is a PCSK9 inhibitor. It works by blocking a protein in your body called PCSK9. Blocking this protein helps your body remove LDL cholesterol from your blood.
Rosuvastatin blocks a substance your body needs to make cholesterol. This lowers the amount of cholesterol in your blood. It helps prevent heart attacks and strokes.
- • Injection site reactions (redness, itching, swelling, pain)
- • Flu
- • Muscle pain
- • Diarrhea
- • Headache
- • Nausea
- • Muscle pain
- • Weakness
- • Constipation
- Myalgia 1,655
- Product Dose Omission 1,364
- Injection Site Pain 1,278
- Muscle Spasms 1,162
- Arthralgia 1,053
- Tiredness 11,698
- Feeling sick to your stomach 10,037
- Difficulty breathing 9,212
- Loose stools 9,199
- Muscle pain 8,784
Serious allergic reactions have happened with Praluent, sometimes requiring hospitalization. If you have signs of a serious allergic reaction, stop using Praluent and get medical help right away.
Rosuvastatin can sometimes cause muscle problems, including rhabdomyolysis. This can damage your kidneys. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness, especially if you also have a fever or feel sick. This medicine can also cause liver problems. Your doctor may do blood tests to check your liver.
There is not enough information about Praluent use during pregnancy to know if it is safe. If you are pregnant or plan to become pregnant, talk to your doctor before using Praluent.
Rosuvastatin can harm your unborn baby. Do not take this medicine if you are pregnant. Breastfeeding is also not recommended while taking rosuvastatin.
Also Compare, Nearby Drugs
Compare alirocumab with
How to Read This alirocumab vs rosuvastatin/ezetimibe Comparison
alirocumab is classified in the PCSK9 Inhibitor drug class, while rosuvastatin/ezetimibe sits within the Statin / Cholesterol Absorption Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, alirocumab has 6,512 submissions while rosuvastatin/ezetimibe has 48,930. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for alirocumab or rosuvastatin/ezetimibe.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.